Peer-reviewed studyPLOS Medicine
Study estimates fewer resistance-related deaths with less antibiotic use
This peer-reviewed observational study, published in PLOS Medicine on October 26, 2026, used global surveillance data from 2000 to 2018 covering over 30 million bacterial isolates from 114 countries. It estimates that 10% lower antibiotic use across drug classes would be associated with 38,000 fewer annual deaths from antimicrobial resistance (AMR) worldwide, about 0.50% of bacterial disease deaths. Because it relies on ecological relationships, the study shows associations rather than direct cause, and its surveillance data under-represent low-resource settings.
- Published
- Oct 26, 2026
DOI 10.1371/journal.pmed.1005140
Preprint, not peer-reviewedbioRxiv
Preprint links a circular RNA to immune cell response in tuberculosis
This preprint, not yet reviewed by other scientists, reports that a circular RNA called Circ_0074371 was lower in monocytes from patients with active pulmonary tuberculosis. In laboratory experiments, the authors say it reduced survival of Mycobacterium tuberculosis inside macrophages and pushed them toward the M1 polarization state. They propose that it works by sequestering miR-4738-3p, a regulator of AMP-activated protein kinase (AMPK).
- Published
- Oct 26, 2026
DOI 10.64898/2026.10.20.760595
Preprint, not peer-reviewedmedRxiv
Preprint says tuberculosis model assumptions change projections for India
This preprint, not yet reviewed by other scientists, is a modelling study of tuberculosis transmission. The authors report that a gamma-distributed model of time spent in the asymptomatic stage fits the data at least as well as the standard exponential model. For India, it projects a slower decline in incidence under the status quo but a larger reduction when active case finding is used.
- Published
- Oct 26, 2026
DOI 10.64898/2026.10.21.26366009
Preprint, not peer-reviewedmedRxiv
Preprint estimates 7.48 million more US adults qualify for GLP-1 receptor agonists
This preprint, not yet reviewed by other scientists, analyses adults in the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2018 against the 2026 cardiovascular-kidney-metabolic (CKM) syndrome guideline. The authors estimate it would newly make 7.48 million US adults eligible for glucagon-like peptide-1 receptor agonists (GLP-1RA), mostly people with overweight and lower cardiovascular risk, and no additional adults for sodium-glucose cotransporter 2 inhibitors (SGLT2i). They add that whether treating these adults improves outcomes cost-efficiently remains to be established.
- Published
- Oct 26, 2026
DOI 10.64898/2026.10.22.26366274
Preprint, not peer-reviewedmedRxiv
Preprint says some AI language models diagnose sepsis more accurately than doctors
This preprint, not yet reviewed by other scientists, tests five large language models (LLMs), which are AI systems that generate text, on six anonymised case descriptions of sepsis, a life-threatening response to infection. The authors compared the models with 353 clinicians and report that after laboratory biomarkers were added, Qwen3.8-27B reached 91% accuracy against 61% for physicians. They also report that language, but not patient sex or age, shifted the models' diagnoses.
- Published
- Oct 26, 2026
DOI 10.64898/2026.10.23.26366291
Preprint, not peer-reviewedmedRxiv
Preprint reports a blood-based method may detect Alzheimer-linked DNA changes
This preprint, not yet reviewed by other scientists, reports that a sensitive method for mapping DNA methylation in cell-free DNA from blood can detect differences between people with and without Alzheimer disease. The authors compare age- and sex-matched participants from the Rush Memory and Aging Project and say the blood changes link to brain-specific alterations. They present the approach as a possible non-invasive tool for biomarker research, not a test ready for use.
- Published
- Oct 26, 2026
DOI 10.64898/2026.10.24.26366278
Preprint, not peer-reviewedbioRxiv
Preprint links anxiety in early Alzheimer's to a specific brain network
This preprint, not yet reviewed by other scientists, analyses magnetic resonance imaging (MRI) and amyloid-beta positron emission tomography (PET) scans from 1,775 cognitively unimpaired older adults. The authors report that greater atrophy in the Alzheimer-related brain network was associated with higher anxiety, independent of depression, and that the anxiety network closely resembles the Alzheimer network. They also say greater atrophy in the anxiety network was associated with cognitive decline over 4.6 years.
- Published
- Oct 26, 2026
DOI 10.64898/2026.10.24.761536
Peer-reviewed studyPLOS Medicine
Systematic review finds most non-drug treatments for back pain cost-effective
This peer-reviewed systematic review, published in PLOS Medicine on October 27, 2026, appraised 20 cost-effectiveness studies of guideline-recommended, non-drug, non-surgical treatments for low back pain. The authors report that most interventions are cost-effective at a willingness-to-pay threshold of £20,000, and that some, including fear and stress reduction and self-management support for chronic pain, may save costs compared with usual care. All of the evidence comes from high-income countries, and evidence from low- and middle-income countries remains limited.
- Published
- Oct 27, 2026
DOI 10.1371/journal.pmed.1005273
Preprint, not peer-reviewedmedRxiv
Preprint links advanced cardiovascular-kidney-metabolic stages to faster cognitive decline
This preprint, not yet reviewed by other scientists, pools data from global aging cohorts covering 28,242 participants, with a mean follow-up of 6.5 years. The authors report that advanced stages (3 and 4) of cardiovascular-kidney-metabolic (CKM) syndrome were associated with faster decline in attention, executive function and language, and with depressive symptoms among cognitively unimpaired people. They estimate modifiable factors accounted for 24.8% of cognitive impairment risk, mainly social isolation, depressive symptoms and physical inactivity.
- Published
- Oct 27, 2026
DOI 10.64898/2026.10.21.26366180
Preprint, not peer-reviewedbioRxiv
Preprint maps natural killer cell changes across 50 diseases
This preprint, not yet reviewed by other scientists, builds a Human NK-cell Atlas (HNKA) from more than 1 million NK cells from 1,632 donors with 50 diseases. The authors report disease-linked shifts in specific NK-cell states, such as interferon-related signals in infection and autoimmunity. They also describe a model, NKceiver, that distinguished 18 diseases and predicted COVID-19 severity from NK-cell expression profiles.
- Published
- Oct 27, 2026
DOI 10.64898/2026.10.22.760478
Preprint, not peer-reviewedbioRxiv
Preprint links influenza to inflammation that may destabilize artery plaque in mice
This preprint, not yet reviewed by other scientists, is a study in mice infected with influenza A that profiles gene activity across the lungs and aorta. The authors report that influenza drove inflammation in both organs and that lung changes were linked to changes in the aorta. They say this may destabilize atherosclerotic plaque during the recovery period after infection.
- Published
- Oct 27, 2026
DOI 10.64898/2026.10.22.761022
Preprint, not peer-reviewedbioRxiv
Preprint links a blood signature to early tuberculosis treatment response
This preprint, not yet reviewed by other scientists, analyses blood samples from people with tuberculosis at baseline and four weeks into treatment across three South African cohorts. The authors report 63 consistently changed genes, including fewer neutrophils, and a signature called EARLY5 that predicted sputum culture conversion by week 4 with a cross-validated area under the curve (AUC) of 0.76. They say the results support further testing in independent cohorts.
- Published
- Oct 27, 2026
DOI 10.64898/2026.10.25.761687
Preprint, not peer-reviewedbioRxiv
Preprint describes DDU384, a new tuberculosis drug candidate, in mouse models
This preprint, not yet reviewed by other scientists, describes DDU384, a compound the authors call a preclinical candidate for tuberculosis after testing in mouse models of infection. The authors say it was effective alone and in drug combinations, and showed potential to shorten treatment in a relapse model. Toxicology studies are under way before any first-in-human trial.
- Published
- Oct 27, 2026
DOI 10.64898/2026.10.26.760366
ProposedUK Government
Draft UK order would change the classification of certain drugs
This is a draft UK statutory instrument, not yet law, which would become law only if approved and made. If made, it would bring certain drugs under the Misuse of Drugs Act 1971 in line with recommendations from the Advisory Council on the Misuse of Drugs, by amending Schedule 2 to the Act, which sets the Class A, Class B and Class C classification of controlled drugs. The document states that a drug's classification affects the criminal penalties for offences relating to it.
- Published
- Oct 27, 2026
ISBN 9780348288254
Final rule, effective Dec 28, 2026Office of the Secretary
Final rule cuts and revises some health IT certification requirements
This final rule, from the Health and Human Services Department (HHS), deregulates health information technology standards and certification programs by removing and revising certain certification criteria and regulatory provisions. The rule says it reduces burden on developers and providers and takes effect on December 28, 2026.
- Published
- Oct 28, 2026
- Effective
- Dec 28, 2026
How to weigh in: No comment period: this is a final rule.
FR Doc. 2026-21943